Todd Lewis Talarico
Corporate Officer/Principal chez IMMUNOGEN, INC.
Profil
Todd Lewis Talarico is currently the Chief Commercial Officer & VP-Market Access at ImmunoGen, Inc. He previously worked as the Director-Product Development at Apex Bioscience, Inc., Vice President-Process Development at Medicago, Inc., and Principal at AlphaVax, Inc. Talarico holds a doctorate degree from North Carolina State University and an undergraduate degree from The Pennsylvania State University.
Postes actifs de Todd Lewis Talarico
| Sociétés | Poste | Début |
|---|---|---|
| IMMUNOGEN, INC. | Corporate Officer/Principal | - |
Anciens postes connus de Todd Lewis Talarico
| Sociétés | Poste | Fin |
|---|---|---|
Medicago, Inc.
 Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | Corporate Officer/Principal | 01/11/2018 |
AlphaVax, Inc.
 AlphaVax, Inc. Pharmaceuticals: MajorHealth Technology AlphaVax, Inc. involves in clinical-stage biopharmaceutical company. It develops vaccine technology bio products. The firm products include Alphavax and pipleline bio products. It focuses on commercial potential of its alphavaccine vector technology in cancer immunotherapy. The company was founded in 1997 and is headquartered in Durham, NC. | Corporate Officer/Principal | - |
Apex Bioscience, Inc.
 Apex Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Apex Bioscience, Inc. develops patented products based upon hemoglobin and nitric oxide technologies. The company was founded by Joseph de Angelo on June 17, 1993 and is headquartered in Chapel Hill, NC. | Corporate Officer/Principal | - |
Formation de Todd Lewis Talarico
| North Carolina State University | Doctorate Degree |
| The Pennsylvania State University | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Apex Bioscience, Inc.
Apex Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Apex Bioscience, Inc. develops patented products based upon hemoglobin and nitric oxide technologies. The company was founded by Joseph de Angelo on June 17, 1993 and is headquartered in Chapel Hill, NC. | Commercial Services |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | Health Technology |
AlphaVax, Inc.
AlphaVax, Inc. Pharmaceuticals: MajorHealth Technology AlphaVax, Inc. involves in clinical-stage biopharmaceutical company. It develops vaccine technology bio products. The firm products include Alphavax and pipleline bio products. It focuses on commercial potential of its alphavaccine vector technology in cancer immunotherapy. The company was founded in 1997 and is headquartered in Durham, NC. | Health Technology |
ImmunoGen, Inc.
 ImmunoGen, Inc. BiotechnologyHealth Technology ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA. | Health Technology |
